[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 82, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 917304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 630312, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 56, "title": "Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 36, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thorsten  Graef M.D., Ph.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 60, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.1, "open": 5.17, "dayLow": 5.01, "dayHigh": 5.4, "regularMarketPreviousClose": 5.1, "regularMarketOpen": 5.17, "regularMarketDayLow": 5.01, "regularMarketDayHigh": 5.4, "payoutRatio": 0.0, "forwardPE": -1.5536232, "volume": 126666, "regularMarketVolume": 126666, "averageVolume": 76667, "averageVolume10days": 81170, "averageDailyVolume10Day": 81170, "bid": 5.29, "ask": 5.41, "bidSize": 1, "askSize": 1, "marketCap": 130190648, "fiftyTwoWeekLow": 3.37, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": 50.054073, "fiftyDayAverage": 6.3974, "twoHundredDayAverage": 10.159652, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -1472201, "profitMargins": 0.0, "floatShares": 4323015, "sharesOutstanding": 24289300, "sharesShort": 1183120, "sharesShortPriorMonth": 1250990, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.048699997, "heldPercentInsiders": 0.21878, "heldPercentInstitutions": 0.91112, "shortRatio": 13.7, "shortPercentOfFloat": 0.049000002, "impliedSharesOutstanding": 24289300, "bookValue": 8.276, "priceToBook": 0.6476559, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -61276000, "trailingEps": -2.48, "forwardEps": -3.45, "enterpriseToRevenue": -0.566, "enterpriseToEbitda": 0.025, "52WeekChange": -0.575, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 5.36, "targetHighPrice": 23.0, "targetLowPrice": 18.0, "targetMeanPrice": 21.0, "targetMedianPrice": 21.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 146631008, "totalCashPerShare": 6.037, "ebitda": -58574000, "totalDebt": 14968000, "quickRatio": 11.137, "currentRatio": 11.327, "totalRevenue": 2601000, "debtToEquity": 7.447, "revenuePerShare": 0.485, "grossProfits": 2601000, "operatingCashflow": -51057000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -23.44675, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketChangePercent": 5.098044, "regularMarketPrice": 5.36, "corporateActions": [], "postMarketTime": 1741395005, "regularMarketTime": 1741381202, "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "postMarketChangePercent": 1.6791, "postMarketPrice": 5.45, "postMarketChange": 0.0899997, "regularMarketChange": 0.26000023, "regularMarketDayRange": "5.01 - 5.4", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 76667, "fiftyTwoWeekLowChange": 1.9900002, "fiftyTwoWeekLowChangePercent": 0.5905045, "fiftyTwoWeekRange": "3.37 - 17.31", "fiftyTwoWeekHighChange": -11.949999, "fiftyTwoWeekHighChangePercent": -0.6903524, "fiftyTwoWeekChangePercent": -57.5, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "epsTrailingTwelveMonths": -2.48, "epsForward": -3.45, "epsCurrentYear": -5.08, "priceEpsCurrentYear": -1.0551182, "fiftyDayAverageChange": -1.0373998, "fiftyDayAverageChangePercent": -0.16215959, "twoHundredDayAverageChange": -4.7996516, "twoHundredDayAverageChangePercent": -0.47242284, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "cryptoTradeable": false, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]